Velorum Therapeutics

Velorum Therapeutics focused on heme dysregulation, a fundamental biological problem underlying multiple serious diseases that existing treatments couldn't adequately address. Patients with conditions like sickle cell disease, beta-thalassemia, and certain cancers experienced severe symptoms because their bodies couldn't properly manage heme metabolism—the iron-containing compound critical to oxygen transport and cellular function. The problem was measurable through biomarkers and clinical outcomes: hemolysis rates, organ damage, and disease progression could be tracked objectively. Existing treatments offered limited options, primarily managing symptoms rather than addressing root causes. Some patients relied on blood transfusions, chelation therapy, or palliative care with significant side effects. Early validation came from foundational research demonstrating that heme accumulation drove pathology in these conditions. Academic publications and preclinical data showed that modulating heme-related pathways could reverse disease mechanisms in laboratory models. Conversations with patient communities and physicians revealed desperate need for mechanism-based approaches. The scientific foundation was strong enough that leading researchers joined the company, and initial partnerships with academic institutions validated that the heme biology approach represented a genuinely novel therapeutic avenue.